Levels of Evidence of Carcinogenicity by unknown
EnvironmentalHealthPerspectives
Vol. 101(Suppl. 1), p. 2 (1993)
Levels of
Evidence of Carcinogenicity
Thefollowing information currently appears at the
beginningofeach TechnicalReporttoinform thereader
ofthe paraneters used to classify the results.
The National Toxicology Program describes the results
of individual experiments on a chemical agent and notes
the strength of evidence for conclusions regarding each
study. Negative results, inwhich the study animals do not
have agreaterincidence ofneoplasiathan control animals,
do not necessarily mean that a chemical is not a carcino-
gen, inasmuch as the experiments are conducted under a
limited setofconditions. Positiveresults demonstratethat
a chemical is carcinogenic for laboratory animals under
the conditions ofthe study and indicate that exposure to
the chemical has the potential forhazard to humans. Five
categories ofevidence ofcarcinogenic activity are used in
the Technical Report series to summarize the strength of
the evidence observed in each experiment: two categories
for positive results (Clear Evidence) and (Some Evi-
dence); one category for uncertain findings (Equivocal
Evidence); one category for no observable effects (No
Evidence); andone categoryforexperiments thatbecause
ofmajor flaws cannot be evaluated (Inadequate Study).
Thesecategoriesofinterpretative conclusionswerefirst
adopted bythe National Toxicology Program in June 1983
and then revised in March 1986 for use in the NTP
Technical Reports series to incorporate more specifically
the concept of actual weight of evidence of carcinogenic
activity. For each separate experiment (male rats, female
rats,malemice,femalemice),oneofthefollowingquintetis
selected to describe the findings. The categories refer to
thestrengthoftheexperimentalevidenceandnottoeither
potencyormechanism.
Clear Evidence of Carcinogenic Activity is demon-
strated bystudies that areinterpreted as showing adose-
related (i) increase ofmalignantneoplasms, (ii)increase of
a combination ofmalignant and benign neoplasms, or (iii)
marked increase ofbenign neoplasms ifthere is anindica-
tionfromthis orotherstudies oftheabilityofsuchtumors
toprogress tomalignancy.
Some Evidence of Carcinogenic Activity is demon-
strated by studies that are interpreted as showing a
chemically-related increased incidence of neoplasms
(malignant, benign, orcombined) inwhich the strength of
the response is less than thatrequired for clear evidence.
Equivocal Evidence of Carcinogenic Activity is demon-
stratedby studies that areinterpreted as showing amargi-
nal increase ofneoplasms that may be chemically related.
No Evidence ofCarcinogenic Activity is demonstrated
by studies that are interpreted as showing no chemically-
related increases in malignant orbenign neoplasms.
Inadequate Study of Carcinogenic Activity is demon-
strated by studies that because of major qualitative or
quantitative limitations cannot be interpreted as valid for
showing either the presence or absence of carcinogenic
activity.
When a conclusion statement for a particular experi-
mentisselected,considerationmustbegiventokeyfactors
that would extend the actual boundary of an individual
categoryofevidence.Thisshouldallowforincorporationof
scientific experience and current understanding of long-
term carcinogenesis studies in laboratory animals,
especially for those evaluations that may be on the bor-
derline between two adjacent levels. These considerations
shouldinclude:
* The adequacy of the experimental design and conduct
* Occurrence ofcommonversus uncommon neoplasia
* Progression (or lack thereof) from benign to malignant
neoplasia as well as from preneoplastic to neoplastic
lesions
* Somebenignneoplasms havethecapacitytoregressbut
others (of the same morphologic type) progress. At
present,itisimpossibletoidentifythedifference.There-
fore, where progression is known to be a possibility,
the most prudent course is to assume that benign neo-
plasms of those types have the potential to become
malignant
* Combining benign and malignant tumor incidences
known or thought to represent stages ofprogression in
the same organ ortissue
* Latencyin tumor induction
* Multiplicityin site-specific neoplasia
* Metastases
* Supporting information from proliferative lesions
(hyperplasia) in the same site of neoplasia or in other
experiments (same lesion in another sex or species)
* The presence or absence ofdose relationships
* The statistical significance of the observed tumor
increase
* The concurrent control tumor incidence as well as the
historical control rate and variability for a specific neo-
plasm
* Survival-adjusted analyses and false positive or false
negativeconcerns
* Structure-activity correlations
* In some cases, genetic toxicology